A self-emulsifying drug delivery system to improve dissolution, stability, andbioavailability of drug compounds of dronabinol or other cannabinoids. Thedrug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixedglycerides and/or free fatty acids containing medium and/or long chain saturated,mono-unsaturated, and/or poly-unsaturated free fatty acids) together withat least one surfactant. The surfactant promotes self-emulsification, therebypromoting targeted chylomicron delivery and optimal bioavailability to a mammalianintestinal lumen. A dosage form can optionally include co-solvents, anti-oxidants,viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP effluxinhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solidformation for targeted release rates.
